Daily Biotech Movers — 2026-07-31: A Clinical-Failure and Class-Derisking Day Inside a Quiet Tape

Friday, July 31, 2026 was a clinical-failure and class-derisking day inside a quiet tape. The S&P 500 ETF rose +0.72%, but the biotech ETF XBI fell -2.94%, IBB fell -1.87%, and XLV fell -0.59%. Within our coverage universe, 149 names finished higher and 417 finished lower, with 566 companies showing a directional move out of 582 tracked. The mean move was -2.09%, the median was -1.56%, and the standard deviation was 7.16%.

The single biggest print was a Phase 3 clinical failure: Karyopharm’s XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer missed its primary PFS endpoint, and KPTI dropped 72.61% on 14.64x volume. The second biggest was a class-level derisking: Novo Nordisk’s Phase 3 ZEUS trial failure reset the entire NLRP3-inhibitor class, and BioAge Labs — whose lead candidate BGE-102 is an oral NLRP3 inhibitor — collapsed 63.62% on 9.69x volume alongside another NLRP3 name, Neumora. The third biggest was a money-show round-trip: Nuwellis gave back 60.90% of Thursday’s +185.71% pediatric-cardiorenal expansion pop after pricing a $3.4M registered direct offering at market. The sector leaderboard was led by Devices — Drug Delivery, up 4.52% across 3 names, followed by Cannabis-related at +2.34%; the broad buckets were lower, with Biologics at -2.91%, Small Molecule Pharma at -2.45%, and Genetics & Genomics at -5.22%. This is a textbook volatility-shock day: the broad market was barely negative, but two single-stock events dragged the mid-cap to small-cap complex into a 7.16% standard-deviation session.

The Distribution

Measure	July 31 reading
Tracked / priced	582
Directional moves	566
Up / down	149 / 417
Mean / median	-2.09% / -1.56%
Standard deviation	7.16%
Anomaly-flagged	108
Price moves of at least 5%	108

The breadth ratio was roughly 1 advancer for every 2.8 decliners. The 7.16% standard deviation is the day’s clearest signal: two of the largest six moves (KPTI at -72.61% and SCYX at +29.76%) were both high-conviction single-stock events, and the remaining four moved in the -60% to -22% range. When the stdev is this wide, the “market” did not move — individual catalysts did.

The 6 Classes of Mover Signal

The six signal classes separate a fundamental repricing from a technical reversal. On July 31, the dominant pattern was Class 2 single-stock clinical or regulatory event — KPTI’s Phase 3 endometrial failure and BIOA’s class-level NLRP3 derisking — combined with Class 5 sell-the-news / capital-structure reset for NUWE. SCYX was a Class 1 halt-release / momentum / short-squeeze signal on top of a late-June AMPK-activator thesis. AEMD was a Class 1 mechanical (reverse split) signal.

1. Halt-release or reverse-split-adjacent. SCYX (+29.76% on 17.20x volume) and AEMD (+17.10% on 6.01x volume) both straddled this class. AEMD’s print was the cleanest: a 1-for-5 reverse stock split effective July 31, 2026 to maintain Nasdaq compliance under Listing Rule 5550(a)(2), plus an intra-day update from the second cohort of the Australian oncology feasibility study showing consistent directional changes. SCYX is harder to file: the 5-day return equals today’s single-session print, the 17.20x volume ratio against a 30-day base of ~83K shares is technically a momentum breakout, and there is no fresh single-day PR. The post-split tape plus the underlying late-June SCY-770 ADPKD clinical re-rating thesis is the most plausible read.

2. Single-stock clinical or regulatory event. KPTI was the day’s defining Class 2 event. The XPORT-EC-042 trial of selinexor as maintenance-only therapy in TP53 wild-type advanced or recurrent endometrial cancer (N=257) failed to meet its primary PFS endpoint, despite a 5.3-month numerical PFS improvement in a modified subgroup. BIOA sits in a related but adjacent class: its Phase 3 failure source was Novo Nordisk’s ZEUS, not its own program, but the 9.69x volume ratio and -63.62% one-day print reflect the same class-level derisking.

3. Buyout or strategic capital. No major Class 3 event on July 31. The closest was NUWE’s $3.4M registered direct offering at market — a small but machine-readable dilution print that re-priced the float after Thursday’s +185.71% Aquadex pediatric cardiorenal pop.

4. Sector rotation. Broad risk-off rotation: XBI -2.94%, IBB -1.87%, XLV -0.59% against SPY +0.72%. The narrow positive leadership came from Devices — Drug Delivery (+4.52% across 3 names) and Cannabis-related (+2.34% across 5 names), with broad buckets lower. The rotation was not a clean money-flow pattern; it was a generalized risk-off with isolated idiosyncratic pockets.

5. Sell-the-news / prior-cycle profit-taking. NUWE was the cleanest Class 5 event: priced at market under Nasdaq rules, 1.31M shares added on top of a hot tape, classic “sell-the-offering-after-the-pop.” The 5-day return of -15.12% understates the round-trip because it averages Thursday’s +135% and Friday’s -60% into a single number.

6. Stealth accumulation / distribution. NRSN (NeuroSense) traded 9.37x normal volume on a small -2.27% move; LEXX (Lexaria Bioscience) traded 4.54x normal volume on a -1.34% move. Both are unresolved flow signals that need one to three sessions of follow-through.

Top 3 Winners — What Drove Them

SCYX — Scynexis — +29.76% on 17.20x volume (flagged: momentum / no clean single-day catalyst)

SCYNEXIS closed at $4.84 after trading 3.18 million shares, or 17.20x its 30-day average of ~83K shares. Five-day momentum was +29.76%, identical to the single-session print, which means the move was concentrated in today’s regular session. The underlying catalyst stack is the SCY-770 AMPK-activator Phase 1 initiation in autosomal dominant polycystic kidney disease (ADPKD) announced on June 30, 2026 (SCYNEXIS IR — June 30 SCY-770 Phase 1 initiation; SCYNEXIS pipeline overview). That is the only fresh clinical catalyst in the recent record, and it is one month old. The 17.20x volume ratio, the equal 5-day-vs-1-day return, and the absence of a fresh single-day PR all point to a momentum breakout on top of the ADPKD re-rating thesis — most likely a short-squeeze or low-float microstructure rather than a fresh disclosure (SCYX stock analysis; SCYX short interest tracker).

This is the kind of move where the catalyst exists but the magnitude is not mechanically supported by the news. Investors should watch whether the next session confirms through volume, or whether the absence of follow-through exposes an overshoot. Signal class: Class 1 / momentum — late-June ADPKD thesis layered with a short-squeeze microstructure. No clean single-day catalyst — flagged.

CNSP — CNS Pharmaceuticals — +19.94% on 1.17x volume is also in the top 3 by % change, but is flagged as no-clean-catalyst and skipped in the deeper synthesis. The print was on only 11,747 shares — an absolute volume of roughly 12K shares — with no fresh press release and a 5-day return of +11.22% that is a continuation of mid-July trading on the legacy Berubicin / TPI 287 glioblastoma thesis (CNS Pharmaceuticals press releases; CNSP Fintel profile). The thin float amplifies the tape; there is no underlying fundamental reset to anchor a deeper read.

AEMD — Aethlon Medical — +17.10% on 6.01x volume

Aethlon Medical closed at $0.66 after trading 1.28 million shares, or 6.01x its 30-day average. The 5-day return of +13.36% tracks the reverse-split announcement on July 30. AEMD filed a Certificate of Change in Nevada on July 30 to authorize a 1-for-5 reverse stock split of its common stock, effective July 31, 2026, aimed at supporting its broader capital-markets and operating plan including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2) (AEMD 1-for-5 reverse split — Trendonify; AEMD reverse-split announcement — TipRanks; Nasdaq equity corporate actions alert 2026-546). The session was compounded by an intra-day update from the second cohort of Aethlon’s Australian oncology feasibility study showing consistent directional changes in Hemopurifier-treated patients (AEMD second-cohort oncology update).

This is a hybrid event: a mechanical reverse split (which mechanically raises the share price without changing market cap) plus a coincident clinical-feasibility update. The 6.01x volume ratio is moderate — significant but not extreme — and the 5-day run-up suggests the rerate began with the July 30 announcement. Signal class: Class 1 / Class 5 hybrid — reverse-split plus clinical-cohort update, with the rerate beginning on the announcement day.

Top 3 Losers — What Drove Them

KPTI — Karyopharm Therapeutics — -72.61% on 14.64x volume

Karyopharm collapsed to $1.92 after trading 22.4 million shares, or 14.64x its 30-day average. The 5-day return of -74.09% captures the cumulative derisking from the July 30 after-hours XPORT-EC-042 topline release plus the prior week’s Pomerantz LLP securities-fraud probe tied to the 2026 Leadership Cash Retention Program. The XPORT-EC-042 trial of selinexor as maintenance-only therapy in TP53 wild-type advanced or recurrent endometrial cancer (N=257) failed to meet its primary PFS endpoint versus placebo, despite a 5.3-month numerical PFS improvement in a modified subgroup (Karyopharm topline XPORT-EC-042 release — investor relations; XPORT-EC-042 topline via PR Newswire). The Friday session was the first full regular-session print of the reaction; pre-market had already dropped ~21% on the announcement.

Management plans to cut endometrial cancer spending while prioritizing myelofibrosis and multiple myeloma programs built around selinexor, but the day’s framing was a “brutal reset of expectations and confidence” in the broader KPTI pipeline story (KPTI coverage — StocksToTrade). The pre-existing securities-fraud probe from Pomerantz LLP — launched after a 2026 Leadership Cash Retention Program granted large lump-sum cash awards to senior executives — had already taken ~21% off the share price; the 14.64x volume on the trial failure indicates the position was already under pressure and the failed readout finalized the unwind (KPTI after-hours coverage — Benzinga). Signal class: Class 2 primary endpoint failure, layered on a Class 5 / Class 3 governance overhang from prior week.

BIOA — BioAge Labs — -63.62% on 9.69x volume

BioAge Labs closed at $9.04 after trading 9.98 million shares, or 9.69x its 30-day average. The 5-day return of -58.47% reflects the cumulative derisking from late-week NLRP3 class news. The fresh catalyst was a class-level reset: Novo Nordisk’s Phase 3 ZEUS trial failed, and BioAge’s lead candidate BGE-102 is an oral NLRP3 inhibitor in the QUELL-CV Phase 2 proof-of-concept in cardiovascular disease plus a planned Phase 1b/2a in diabetic macular edema, with QUELL-CV top-line expected in 2H 2026 (Why BioAge Labs is sinking — Benzinga; BGE-102 Phase 1 NLRP3 data — Benzinga press release). Following the ZEUS results, William Blair maintained its Market Perform rating on BioAge, writing that “despite plans to examine BGE-102 in ophthalmology indications, we believe the approach remains high risk and difficult to build an investment thesis around.” Same-day, Neumora Therapeutics (NMRA) traded down on its CNS-penetrant NLRP3 inhibitor NMRA-215, confirming the class-level read.

For BioAge, the new valuation framework materially reduces the BGE-102 opportunity’s contribution to the story. The broader question is whether the QUELL-CV top-line (still expected 2H 2026) can re-establish a thesis, or whether the class reset from ZEUS is permanent. Signal class: Class 2 / class-level — adjacent-name Phase 3 failure resetting an entire drug class.

NUWE — Nuwellis — -60.90% on 1.41x volume

Nuwellis fell to $1.74 after trading 6.87 million shares, or 1.41x its 30-day average. The 5-day return of -15.12% understates the round-trip because it averages Thursday’s +135.45% pediatric-cardiorenal expansion pop into a single number. On Friday, the company announced pricing of a $3.4M registered direct offering of 1,310,890 shares at market under Nasdaq rules — a clean dilution print that re-prices the float for a small-cap medical-device story that had just run on Thursday’s Aquadex pediatric cardiorenal expansion thesis and preliminary Q2 2026 guidance of ~14% YoY Q2 revenue growth and ~20% H1 growth (NUWE $3.4M registered direct offering — MarketChameleon; Nuwellis Slumps on Share Sale — Baystreet; NUWE offering coverage — Seeking Alpha).

The 1.41x volume ratio is modest in absolute terms — this is not a forced-selling or retail-driven halt. The market was repricing the capital structure rather than the underlying Aquadex thesis. The question is whether the offering is large enough to disturb the company’s medium-term runway or whether it is a routine top-up financing on a tape that was overdue for consolidation. Signal class: Class 5 — sell-the-offering-after-the-pop.

The Cross-Cutting Pattern

The day’s pattern was a clinical-failure day with a class-level echo and a money-show round-trip. The single biggest move (KPTI -72.61%) was a direct same-day-or-prior trial readout; the second biggest (BIOA -63.62%) was a class-level reset triggered by a peer readout; the third biggest (NUWE -60.90%) was a textbook “sell-the-offering-after-the-pop” event. The winners’ side was more uniform: SCYX was a momentum breakout on top of a late-June AMPK-activator thesis, AEMD was a reverse-split-plus-clinical-update hybrid, and CNSP was a thin-float tape move with no clean catalyst.

The sector data confirms the risk-off framing. Broad buckets — Biologics (-2.91%), Small Molecule Pharma (-2.45%), Stem Cells / Cellular Therapy (-2.33%), Diagnostics (-2.36%), RNA / Peptide / Gene Therapy (-2.22%) — were lower. The two narrow positive leadership groups (Devices — Drug Delivery at +4.52% across 3 names, Cannabis-related at +2.34% across 5 names) are too small to be reliable signals. What this tells us is that the day’s -2.09% mean and -1.56% median were not the result of a broad de-risking event — they were the result of two specific large-cap clinical events (KPTI -72.61% and BIOA -63.62%) dragging the broader complex. If we excluded those two names, the mean move would be substantially less negative.

The volume profile reinforces this: the top 6 volume anomalies were SCYX (+29.76% on 17.20x), KPTI (-72.61% on 14.64x), MBRX (-60.78% on 12.41x), BIOA (-63.62% on 9.69x), NRSN (-2.27% on 9.37x), and MYGN (-46.74% on 8.34x). Five of the six are high-conviction single-stock events; only NRSN is a stealth-mover signal. In a quiet tape, the 108 anomaly flags are all idiosyncratic — there is no “broad market” story here.

The 5 Data Points That Matter

1. Percentage change versus the sector baseline. KPTI underperformed the coverage-universe median by roughly 71.0 percentage points; NUWE by 59.3 points; BIOA by 62.1 points. SCYX beat the median by 31.3 points; AEMD by 18.7 points. These are not beta plays — they are individual catalyst prints.

2. Volume ratio. KPTI’s 14.64x and SCYX’s 17.20x were the strongest top-six confirmations. BIOA’s 9.69x showed that the class-derisking move was heavily participated. NUWE’s 1.41x and AEMD’s 6.01x were less extreme but sufficient. For the stealth movers, NRSN’s 9.37x on a small price move is the strongest accumulation/distribution signal on the day.

3. Five-day momentum. KPTI’s -72.61% day against -74.09% five-day momentum is the cleanest “the news reset the trajectory” pattern. BIOA’s -63.62% against -58.47% is class-derisking on top of an already-weaker tape. NUWE’s -60.90% against -15.12% is the round-trip print. SCYX’s +29.76% against +29.76% is one-day-everything. AEMD’s +17.10% against +13.36% is a continuation move.

4. 52-week positioning. The full report places KPTI at $1.92 against a year range that now reflects the post-failure reset, BIOA at $9.04 against a range that previously accommodated the full NLRP3 thesis, NUWE at $1.74 against a range that compresses the prior Thursday’s +135% into a single print, SCYX at $4.84 against a range that brackets the late-June ADPKD re-rating, and AEMD at $0.66 against a post-reverse-split band that is not directly comparable to prior 52-week readings.

5. Cash and dilution context. KPTI’s Phase 3 failure plus the existing Pomerantz LLP governance probe heightens dilution sensitivity going forward. BIOA’s class-level reset narrows the runway for BGE-102 development outside the original QUELL-CV indication. NUWE’s registered direct offering is small ($3.4M) but adds 1.31M shares on top of a very thin float. SCYX is the post-clinical-milestone thesis that the market is still digesting. AEMD’s reverse split is explicitly framed as a dilution-management tool, which means the float is still under pressure even after the mechanical recomputation.

What This Synthesis Will and Won’t Tell You

This synthesis identifies the July 31 distribution, ranks the six largest price movers, and distinguishes fresh clinical and capital-structure disclosures from momentum and class-derisking events. The cleanest signal is the concentration of clinical-failure and class-level pain at the top of the losers list: KPTI’s Phase 3 XPORT-EC-042 missed the primary endpoint, BIOA’s class thesis was reset by Novo Nordisk’s ZEUS, and NUWE gave back its prior-day pop on a small offering. The winners were more uniform — a momentum breakout, a reverse-split-plus-clinical-update, and a thin-float tape move with no clean catalyst.

It will not tell you whether Karyopharm’s myelofibrosis and multiple myeloma programs can rebuild the selinexor thesis, whether BioAge’s QUELL-CV top-line can re-establish the BGE-102 opportunity, whether Nuwellis’s pediatric cardiorenal expansion can sustain the original Aquadex narrative, whether the SCY-770 AMPK-activator program in ADPKD will translate into a clinical asset, or whether Aethlon’s Hemopurifier second-cohort data will sustain the rerate. One day is one day. The 108 anomaly flags describe dispersion, not a durable portfolio signal; the next three sessions will show whether continuation on volume validates a winner or fading volume exposes an overshoot. Only Karyopharm Therapeutics currently matches a verified company profile among the six movers, an explicit coverage gap that does not change the analysis.

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-07-31 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: Karyopharm topline XPORT-EC-042 release — investor relations; XPORT-EC-042 topline via PR Newswire; KPTI after-hours coverage — Benzinga; KPTI coverage — StocksToTrade; Why BioAge Labs is sinking — Benzinga; BGE-102 Phase 1 NLRP3 data — Benzinga press release; NUWE $3.4M registered direct offering — MarketChameleon; Nuwellis Slumps on Share Sale — Baystreet; NUWE offering coverage — Seeking Alpha; SCYNEXIS IR — June 30 SCY-770 Phase 1 initiation; SCYNEXIS pipeline overview; SCYX stock analysis; SCYX short interest tracker; AEMD 1-for-5 reverse split — Trendonify; AEMD reverse-split announcement — TipRanks; Nasdaq equity corporate actions alert 2026-546; AEMD second-cohort oncology update; CNS Pharmaceuticals press releases; CNSP Fintel profile; CNSP stock split history.